Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 15% below Graham Number — thin margin of safety
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 7.7% — below-average profitability
- Revenue growing at 5% annually
CONMED CORPORATION (CNMD) is a Healthcare company operating in Electromedical & Electrotherapeutic Apparatus, listed on the NYSE , with a market capitalisation of $1.1 billion . Key value metrics: P/E ratio 14.5, P/B ratio 1.11, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
CONMED CORPORATION — Fundamental Analysis Summary
CONMED CORPORATION (CNMD) is trading 15% below its Graham Number of $44.03, offering a thin margin of safety. The stock carries a reasonable trailing P/E ratio of 14.5x.
On financial health, CNMD shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 7.7% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.86.
StockPik's composite Value Score for CNMD is 93/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CNMD reports a solid gross margin of 54.0% (sector average: 33.5%) and a modest operating margin of 10.0%.
CNMD shows revenue growing at 5% year-over-year, with earnings declining at 64%.
CNMD pays a modest dividend yield of 2.1%.